In vitro anti-platelet potency of ticagrelor in blood samples from infants and children. Issue 3 (September 2015)

• Record Type: Journal Article
• Authors: Söderlund, Fredrik; Asztély, Anna-Karin; Jeppsson, Anders; Nylander, Sven; Berggren, Anders; Nelander, Karin; Castellheim, Albert; Romlin, Birgitta S.
• Is Part Of: Thrombosis research. Volume 136:Issue 3(2015)
• Page Start: 620
• Page End: 624
• Publication Date: 2015-09
• Subjects: Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2015.07.013
• Languages: English
• ISSNs: 0049-3848

Abstract

<abstract abstract-type="author" id="ab0005"> <title id="st0005">Abstract</title> <sec> <title id="st0010">Introduction</title> <p id="sp0005">Ticagrelor, a novel platelet inhibitor acting on the ADP-dependent P2Y<sub>12</sub> receptor, is currently approved for treating adults with acute coronary syndrome. The effect of ticagrelor in children has not been explored. As a first step, we here evaluate if the <italic>in vitro</italic> anti-platelet potency of ticagrelor in blood samples from children of different age is different as compared with in blood samples from adults.</p> </sec> <sec> <title id="st0015">Materials and Methods</title> <p id="sp0010">Blood samples from 36 healthy children grouped by age (0–2 months, n = 6; 2–6 months, n = 6; 6 months-2 years, n = 6; 2–6 years, n = 10; 6–12 years, n = 8) and 13 adults were collected for <italic>in vitro</italic> analysis using vasodilator stimulated phosphoprotein phosphorylation (VASP) assay in whole blood and ADP-induced light transmission aggregometry (LTA) in platelet rich plasma. Ticagrelor (0.01 – 10 μmol/L) was added <italic>in vitro</italic> and its potency was assessed by calculating the concentration that provided 50% inhibition of the maximum response (IC<sub>50</sub>).</p> </sec> <sec> <title id="st0020">Results</title> <p id="sp0015">The in vitro potency of ticagrelor in blood from adults and in blood from children of any age group were comparable, both when analyzed with LTA and with VASP.</p> </sec> <sec> <title id="st0025">Conclusions</title> <p id="sp0020">These <italic>in vitro</italic> results are consistent with the hypothesis that ticagrelor would achieve a comparable anti-platelet effect in children of different ages as in adults at equal plasma exposure.</p> </sec> </abstract>